 |
News
-
WHO-South Korea biomanufacturing training hub initiative (September 2022)
Read More -
Generic and Biosimilar Medicines, Central to Patient Health and Global Healthcare Policies (September 2022)
Experts and leaders from the local and global generic and biosimilar medicines industry, Government and UN agencies, patient organizations, academia and other stakeholders are meeting from 7 to 9 September in Kuala Lumpur, Malaysia to discuss key topics affecting worldwide
… Read More -
ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine (28 July 2022)
MPP invites Expressions of Interest (EoI) from potential sublicensees based anywhere in the world for sublicences to manufacture and sell the cabotegravir long-acting injectable in the licensed territory.
Read More -
UICC announces a new global coalition to increase access to and the use of essential cancer medicines in low- and lower middle-income countries (May 2022)
GENEVA, SWITZERLAND / AGILITYPR.NEWS / May 20, 2022 / The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer medicines in low- and
… Read More -
IGBA’s Newly Launched CEO Advisory Committee Holds Inaugural Meeting with WTO Director General (May 2022)
The newly established IGBA CEO Advisory Committee , a forum for generic and biosimilar medicines industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy matters, held its inaugural meeting on
… Read More -
IGBA establishes a CEO Advisory Committee (February 2022, Committee updated)
The International Generic and Biosimilar medicines Association (IGBA) announced today that it has established a CEO Advisory Committee composed of fourteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States.
Read More -
Generics Industry At The Forefront In War Against COVID-19 In 2021: Generics Bulletin (informa.com) (January 2022)
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
Read More -
GENEZIS, the Serbian and Montenegrin Generic and Biosimilar Medicines Association, joins IGBA (January 2022)
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that GENEZIS has been accepted and welcomed as a new IGBA Associate Member.
Read More -
Vivian Frittelli takes over the position of IGBA Chair (January 2022)
IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Vivian Frittelli, Chief Executive of Generic and Biosimilar Medicines of Southern Africa (GBM), is taking over the position of IGBA
… Read More -
IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access (November 2021)
Geneva, November 1 st , 2021 –In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The second Global Biosimilars Week
… Read More -
Global Biosimilars Week: Message of Sudarshan Jain, Chair, IGBA (October 2021)
Read More -
Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid (October 2021)
07 October, Athens, Greece. Health systems have been severely jolted by COVID-19, causing widespread disruption to the provision of health care worldwide. As countries shift to investment in healthcare system recovery and ongoing management of COVID-19, off-patent medicines will be
… Read More
- 1
- 2
- 3
- 4
- 5
- 6
- 7
Our Mission and Vision
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
Introduction
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).
